Verastem Oncology "announced that an abstract highlighting updated interim results from Part A of the ongoing Phase 2, registration-directed RAMP 201 trial evaluating avutometinib and defactinib in patients with low-grade serous ovarian cancer has been selected for a presentation in a Poster Discussion Session at the upcoming American Society of Clinical Oncology Annual Meeting taking place June 2-6, 2023 in Chicago, IL. The objective of Part A of the RAMP201 LGSOC study was to determine the go forward regimen between avutometinib monotherapy or the combination of avutometinib and defactinib to be studied in Part B of the study. The efficacy and safety of each regimen were assessed in both KRAS mutant and KRAS wild-type recurrent LGSOC. The ongoing expansion Phase of the trial, which is fully enrolled, will evaluate the efficacy and safety of the regimen selected. The Company is in ongoing discussions with the U.S. Food and Drug Administration on confirmatory study plans and intends to provide an update after agreement with the FDA. Continued enrollment in the combination arm of RAMP 201 is planned to expand the clinical experience in anticipation of initiation of a confirmatory study."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VSTM:
